BioCatalystWatch
SCYXWorkspace / SCYX / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026SCY-770 — planned ADPKD Phase 2 proof-of-concept study · Trial initiationCompany source ↗
Cash

Chart & Events

Candle interval

Core Clinical

BREXAFEMME® (ibrexafungerp tablets)

Glucan synthase

Approved

PreINDP1P2P3FilingApproved
SCY-247

Glucan synthase complex

PreINDP1P3FilingApproved
Upcoming / outlook

SCY-770

AMPK

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SCY-770

AMPK

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

SCY-247

Glucan synthase complex

PreINDP1P3FilingApproved
Upcoming / outlook

BREXAFEMME® (ibrexafungerp tablets)

Glucan synthase

Approved

PreINDP1P2P3FilingApproved

Other pipelines

SCY-247

Glucan synthase complex

PreINDP1P2P3FilingApproved
Upcoming / outlook

SCY-247 oral formulation

PreINDP1P2P3FilingApproved
SCY-247 oral formulation

PreINDP1P2P3FilingApproved
SCY-247

Glucan synthase complex

SCY-770

AMPK

Partner / License out

Approved / commercial

History / paused

SCY-770

AMPK

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

SCYX SEC archive